Clinical trials: Pulmonary Hypertension
Healthy
Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl
This is an open-label study to evaluate the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. The study will consist of: Screening evaluations (within 29 days prior to dosing); a treatment phase (from dosing…
- Trial name
- NCT05006118
- Testing
- Radio-labeled rodatristat ethyl 600 mg
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.
- Trial name
- NCT05167825
- Testing
- Macitentan
- Where
- 11 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery
This is an open-label, multicenter study evaluating the dose, effect, safety and tolerability of intravenous PDNO infusion given to patients undergoing cardiopulmonary bypass (CPB) surgery with post-operative acute pulmonary…
- Trial name
- NCT05699486
- Testing
- PDNO
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Attgeno AB
Pulmonary Arterial Hypertension
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101.
- Trial name
- IMPAHCT-FUL (NCT05557942)
- Testing
- AV-101
- Where
- 72 sites in United States, Argentina and 18 more
- Volunteers
- 186 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension
Ventavis® Registry Protocol
The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3…
- Trial name
- RESPIRE (NCT00902603)
- Testing
- Commercial Ventavis® (iloprost)
- Volunteers
- 148 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Dilated Cardiomyopathy
IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy
IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension, Dilated Cardiomyopathy, Congenital Heart Disease
- Trial name
- HEARTFUL-CHD (NCT06072937)
- Testing
- IntelliStent
- Volunteers
- 10 people
- Sponsor
- HeartPoint Global
Heart Failure, Pulmonary Arterial Hypertension
Non-invasive Pulmonary Artery Prediction
Cardiac remote monitoring devices have expanded our ability to track physiological changes used in the diagnosis and management of patients with cardiac disease.
- Trial name
- ADOPTS (NCT05622695)
- Testing
- catheterization
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Silverleaf Medical Sciences INC
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Trial name
- NCT00345774
- Testing
- PRX-08066
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
- Trial name
- GRIPHON (NCT01106014)
- Testing
- Selexipag
- Where
- 182 sites in United States, Argentina and 37 more
- Volunteers
- 1,156 people
- Sponsor
- Actelion
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Pulmonary Arterial Hypertension
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
To observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related…
- Trial name
- EVOLVE (NCT05060315)
- Testing
- Remunity Pump for Remodulin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
Pulmonary Arterial Hypertension
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities
The purpose of this study is to compare the bioavailability of a single 1mg dose of treprostinil diethanolamine sustained release (SR) tablets manufactured by two independent facilities.
- Trial name
- NCT01165476
- Testing
- Treprostinil diethanolamine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.
- Trial name
- NCT04041648
- Testing
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Sleep Apnea, Asthma
Sleepiz One+ vs. Capnography and Electrocardiography
Respiratory Rate (RR) and heart rate (HR) are vital signs crucial for assessing a patient's overall health, providing insights into various conditions and stressors.
- Conditions
- Sleep Apnea, Asthma, COPD, Hypertension
- Trial name
- NCT06569940
- Testing
- Sleepiz One+
- Where
- Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sleepiz AG
Pulmonary Arterial Hypertension
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
To investigate the long-term safety and effectiveness of Adcirca (tadalafil) in Pulmonary Arterial Hypertension (PAH) patients in the clinical practice -focused topics- 1.
- Trial name
- NCT01066845
- Testing
- tadalafil
- Volunteers
- 1,809 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06388421
- Testing
- Prospective study assessments
- Where
- 71 sites in United States, Puerto Rico
- Volunteers
- 900 people
- Sponsor
- United Therapeutics
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics